The launch of the "five rectification" special action for medical devices led the corresponding sectors to rise in a high profile yesterday. Among them, Yangpu medical limited rose, while Tongce medical, baolaite, Jiuan medical, Aier ophthalmology and Guanhao biology all rose more than 5%. At this time, starting the special action to rectify the medical device industry will promote the orderly development of the industry, and the relevant listed companies are expected to benefit from it.

On March 17, the State Food and Drug Administration announced at a press conference that in order to solve the hot and difficult problems of medical devices with high social concern and strong public response, further standardize the market order and severely crack down on violations of laws and regulations, the State Food and Drug Administration decided to launch a five month "five rectification" special action for medical devices nationwide from mid March, Focus on the rectification of medical devices false registration declaration, illegal production, illegal business, exaggerated publicity, the use of unlicensed products and other five acts.

In recent years, China's medical device industry has developed rapidly, and the overall security situation is stable and good. However, due to the late development of China's medical device industry, the overall scale of the industry is small, and the industrial foundation is relatively weak, some enterprises' violations occur from time to time, and some product quality and safety risks exist. In this regard, the food and drug administration hopes to carry out this special action to create a high-pressure situation of severely cracking down on violations of laws and regulations of medical devices, effectively punish violations of laws and regulations, further improve the regulatory system and mechanism, so as to achieve the purpose of regulating a kind of product, standardizing a kind of behavior, and effectively guarantee the safety of public use of equipment.

In fact, at the beginning of this year, dozens of listed pharmaceutical companies have collectively suspended their business to plan major events, and a new round of mergers and acquisitions in the pharmaceutical industry has begun. According to the analysis of pharmaceutical industry researchers, most of the M & A targets are listed medical device companies, and most of the M & A targets are related to medical services and medical device assets.

In addition, under the guidance of the national medical service policy, medical devices are also considered by the industry as one of the areas with the most investment value in the capital market this year. Sanjiang capital told reporters that the company will continue to focus on the layout of medical devices this year, especially in the field of traditional medical devices dominated by orthopedics, which will be the focus of the company in the future. And this investment idea is also recognized by such well-known PE tycoons as Tongchuang Weiye and Jiuding investment. It can be seen that in many pharmaceutical industry segments, the medical device industry will continue the early M & a boom.

Industry insiders believe that with the five month "five rectification" special action of medical devices launched by the state, the business environment of the medical device market will be optimized, which will help accelerate the survival of the fittest. Leading medical device enterprises such as Yuyue medical, Lepu medical, Yangpu medical, Tongce medical and baolaite are expected to benefit from it, Brand influence and market share will be further expanded.